|
Hikma Pharmaceuticals PLC (Hikma), a global pharma company helps put better health within reach every day for millions of people around the world, announced the appointment of Rebecca Hall as chief financial officer (CFO) and executive director.
Rebecca (Becky) will join Hikma Pharmaceuticals in Q1 2027. Hikma will confirm the date of Becky’s appointment in due course.
Becky joins Hikma Pharmaceuticals from ViiV Healthcare, the global specialist HIV pharmaceutical company majority owned by GSK, with Shionogi as a shareholder, where she is senior vice president and chief financial officer, responsible for finance, supply chain and business development.
In 2025, ViiV Healthcare generated revenue of close to £8 billion and delivered 11 per cent growth. Becky brings more than twenty years of experience from ViiV Healthcare and GSK, spanning pharmaceuticals and consumer products. She has also worked across three continents, having been based in London, the US, where she led ViiV Finance for North America, and Singapore, where she led supply chain finance for Asia Pacific, Latin America and Middle East and North Africa.
Commenting on the appointment, Said Darwazah, Hikma Pharmaceuticals’ CEO, said: “I am delighted to welcome Becky to Hikma. She is an accomplished pharmaceutical leader who most recently led the finance department for a multi-billion-pound specialist pharmaceutical business, with experience extending into a broad range of organisational functions. She brings financial and operational discipline that will support the delivery of our strategic plans. I would also like to thank Areb Kurdi for stepping into the acting CFO role and for his support in delivering on our strategic priorities. Areb will continue as acting CFO until Becky joins.”
Victoria Hull, chair of Hikma’s board of directors, said: “Becky’s appointment is a further step in broadening the expertise we have across both the executive team and the Board, positioning us well for long-term sustainable growth.”
Becky Hall, CFO designate of Hikma Pharmaceuticals, added: “For more than 45 years, Hikma has built a strong track record of making high-quality medicines accessible to millions of people around the world. I am delighted to be joining the team and look forward to helping deliver Hikma’s growth ambitions and creating lasting value for patients, shareholders and colleagues.”
As Hikma Group CFO, Becky will join the board as an executive director, replacing Khalid Nabilsi who will step down from the Board on 31st December, 2026. Khalid will continue to serve on the executive committee in his role as deputy CEO, North America and Europe.
Becky Hall spent the first fourteen years of her career at GSK, progressing through commercial, strategic, corporate and supply chain finance roles across the UK, Europe and emerging markets. She also served as chief of staff to the GSK group CFO in the CEO office.
Becky joined ViiV Healthcare in 2018 as global finance controller and commercial strategy finance lead, before moving to the US as vice president and head of North America Finance. She was appointed senior vice president and chief financial officer of ViiV in 2024. She holds a BSc in Economics from the University of Durham and qualified as a CIMA accountant in 2007.
Hikma confirms there is no further information required to be disclosed in relation to Rebecca Hall's appointment as a director pursuant to UK Listing Rule 6.4.8R.
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them.
|